Neuroscience
Neurotransmitter receptors function via various G-protein coupled and G-protein independent mechanisms that activate downstream intracellular signaling pathways such as cAMP/PKA, PI3K/AKT, phospholipase A2, and phospholipase C pathways. For instance, dopamine receptors act through adenylate cyclase to activate PKA and other signaling molecules, thereby mediate gene expression through the actions of CREB and other transcription factors. Other neurotransmitters such as NMDAR or AMPAR are associated with ion channels that control flux of Ca2+ and Na+, thus propagating the action potential across the post-synaptic neuron.
Dysfunctions in GABAergic/glutamatergic/serotonergic/dopaminergic pathways result in a broad range of neurological disorders such as chronic pain, neurodegenerative diseases, and insomnia, as well as mental disorders including schizophrenia, bipolar disorder, depression, and addiction.
-
A3900 Umeclidinium bromideSummary: MAChR antagonist
-
A3918 VilazodoneSummary: Combined SSRI and 5-HT1A receptor partial agonist
-
A3919 Vilazodone HydrochlorideSummary: Combined SSRI and 5-HT1A receptor partial agonist
-
A3926 VortioxetineTarget: 5-HT1 Receptors|5-HT7 Receptors|5-HT3 Receptors|SERTSummary: 5-HT receptors antagonist
-
A3933 WAY-100635Summary: 5-HT1A receptor antagonist,potent and selective
-
A3952 ZiprasidoneSummary: 5-HT (serotonin)/dopamine receptor antagonist
-
A3953 Ziprasidone hydrochloride monohydrateSummary: 5-HT (serotonin)/dopamine receptor antagonist
-
A1114 Parathyroid Hormone (1-34), bovineSummary: Enhancer of blood calcium level
-
A1134 Agouti-related Protein (AGRP) (25-82), humanTarget: Melanocortin (MC) ReceptorsSummary: Agouti-related peptide(25-82)
-
A1932 (-)-Huperzine ATarget: NMDA Receptors|AChESummary: NMDA receptor antagonist/AChE inhibitor